Indication
Details coming soon
Know Medicine, Follow Guideline
Details coming soon
Details coming soon
Details coming soon
| Clinical Information | Administration Information |
|---|---|
|
Indication: Active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 Age: 2 through 55 years |
Dose: Intramuscular injection – 0.5 mL Frequency: Single dose Note: Primary Vaccination |
|
Indication: Active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 Age: 15 through 55 years Condition: At continued risk for meningococcal disease |
Dose: Intramuscular injection – Single booster dose Note: Booster Vaccination; may be given if at least 4 years have elapsed since the prior dose |
| Clinical Information | Administration Information |
|---|---|
|
Indication: Active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 Age: Children 9 through 23 months of age |
Dose: Intramuscular injection – Two doses Frequency: three months apart Note: Primary Vaccination |
|
Indication: Active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 Age: individuals 15 through 55 years of age Condition: at continued risk for meningococcal disease |
Dose: Intramuscular injection – 0.5 mL Note: Booster Vaccination; a single booster dose may be given if at least 4 years have elapsed since the prior dose |
Administer as a 0.5 mL intramuscular injection, preferably into the anterolateral aspect of the thigh for infants and the deltoid muscle for older children and adults. For Menveo, reconstitute the lyophilized MenA component with the liquid MenCYW-135 component and shake well; Menactra and MenQuadfi are supplied as ready-to-use solutions. Dosing schedules vary by age and product: infants may require a 2-dose or 4-dose primary series starting as early as 6 weeks, while individuals 2 years and older typically receive a single dose. Booster doses are recommended for those at continued high risk. Do not administer intravenously, subcutaneously, or intradermally. Syncope may occur following vaccination; observe patients for 15 minutes post-injection. This vaccine should not be given to individuals with a history of severe allergic reaction to any vaccine component or previous dose.
Details coming soon
Details coming soon
Details coming soon
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.